Effect of hospital ownership status and payment structure on the adoption and use of drug-eluting stents for percutaneous coronary interventions

CMAJ. Canadian Medical Association Journal

Volumn 176, Issue 2, 2007, Pages 185-190

  Grilli, Roberto ^a   Guastaroba, Paolo ^a   Taroni, Francesco ^b  

^a Agenzia Sanitaria Regionale   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG ELUTING STENT; FEMALE; HEALTH CARE SYSTEM; HEART SURGERY; HIGH RISK PATIENT; HOSPITAL CARE; HOSPITAL MANAGEMENT; HOSPITAL ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION;

EID: 33846491277     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060385     Document Type: Article

References (34)

1. Grilli R, Taroni F. Managing the introduction of expensive medical procedures: use of a registry. J Health Serv Res Policy 2006;11:89-93.
2. Chu WW, Waksman R. Contemporary use of drug-eluting stents. Curr Treat Options Cardiovasc Med 2005;7:35-46.
3. Maynard C, Lowy E, Wagner T, et al. Utilization of drug-eluting stents in the Veterans Health Administration. Am J Cardiol 2005;96:218-20.
4. Swanson N, Gershlick AH. Drug eluting stents in interventional cardiology - current evidence and emerging uses. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:313-21.
5. Thompson CA, Kaplan AV, Jayne JE, et al. Impact and temporal trends of percutaneous coronary intervention in the drug-eluting stent versus bare metal stent eras. Am J Cardiol 2005;96:668-72.
6. Dash P. New providers in UK health care. BMJ 2004;328:340-2.
7. McIntosh T. Don't panic: the hitchhiker's guide to Chaoulli, wait times and the politics of private insurance. Canadian Policy Research Networks: 2006 Feb 24. Available: www.cprn.com/en/doc.cfm?doc=1394# (accessed 2006 Oct 31).
8. Institute of Medicine. Assessing medical technologies. Washington: National Academy Press; 1985.
9. Sloan FA, Trodgon JG, Curtis LH, et al. Does the ownership of the admitting hospital make a difference? Outcomes and process of care of Medicare beneficiaries admitted with acute myocardial infarction. Med Care 2003;41:1193-205.
10. Devereaux PJ, Schunemann HJ, Ravindran N, et al. Comparison of mortality between private for-profit and private not-for-profit hemodialysis centres. A systematic review and meta-analysis. JAMA 2002;288:2449-57.
11. Devereaux PJ, Choi PT, Lacchetti C, et al. A systematic review and meta-analysis of studies comparing mortality rates of private for-profit and private not-for-profit hospitals. CMAJ 2002;166:1399-406.
12. France G, Taroni F. The evolution of health policy making in Italy. J Health Polit Policy Law 2005;30:169-87.
13. France G, Taroni F, Donatini A. The Italian health-care system. Health Econ 2005; 14:S187-202.
14. Nobilio L, Fortuna D, Vizioli M, et al. Impact of regionalisation of cardiac surgery in Emilia-Romagna, Italy. J Epidemiol Community Health 2004;58:97-102.
15. Marzocchi A, Piovaccari G, Manari A, et al. Comparison of effectiveness of sirolimus-eluting stents vs bare metal stents for percutaneous coronary intervention in patient at high risk for coronary restenosis or clinical adverse events. Am J Cardiol 2005;95:1409-14.
16. Brophy IM, Erickson LJ. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. Int J Technol Assess Health Care 2005;21:326-33.
17. Shrive FM, Manns BJ, Galbraith PD, et al; APPROACH Investigators. Economic evaluation of sirolimus-eluting stents. CMAJ 2005;172:345-51.
18. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons; 1989.
19. Black N, Payne M. Directory of clinical databases: improving and promoting their use. Qual Saf Health Care 2003;12:348-52.
20. Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis ot interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27: 299-309.
21. Draper N, Smith H. Applied regression analysis. New York: Wiley; 1981.
22. Guastaroba P, Fiorini M, Grilli R. Valutazione dell'impatto clinico ed economico della strategia di adozione degli stent a rilascio di farmaco per gli interventi di angioplastica coronarica [Report no 91]. Bologna (Italy): Agenzia Sanitaria Regionale; 2004.
23. Medical Technology and Costs of the Medicare Program Advisory Panel. Diagnosis-related groups (DRGs) and the medicare program: implications for medical technology. A technical memorandum. Washington: US Congress, Office of Technology Assessment; 1983. Available: http://govinfo.library.unt.edu/ota/ Ota_4/DATA/1983/8306.PDF (accessed 2006 Oct 31).
24. Huckman RS. The utilization of competing technologies within the firm: evidence from cardiac procedures. Manage Sci 2003;49:599-617.
25. Huckman RS, Pisano GP. Turf battles in coronary revascularization. N Engl J Med 2005;352:857-9.
26. Horwitz JR. Does corporate ownership matter? Service provision in the hospital industry [NBER Working Paper no 11376]. Cambridge (MA): National Bureau of Economic Research; 2005.
27. Ferguson B, Rice N, Sykes D, et al. Hospital volume and health care outcomes, costs and patient access. Eff Health Care 1996;2(8). Available: www.york.ac.uk/inst/crd/ehc28.pdf (accessed 2006 Oct 31).
28. Gandjour A, Bannenberg A, Lauterbach KW. Threshold volumes associated with higher survival in health care. A systematic review. Med Care 2003;41:1129-41.
29. Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med 2002; 137:511-20.
30. Sowden A, Aletras V, Place M, et al. Volume of clinical activity in hospitals and healthcare outcomes, costs, and patient access. Qual Health Care 1997;6:109-14.
31. Christensen CH. The innovator's dilemma: when new technologies cause great firms to fail. Boston: Harvard Business School Press; 1997.
32. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol 2004;43:513-8.
33. Bagust A, Grayson AD, Palmer ND, et al. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study. Heart 2006;92:68-74.
34. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effectivitats Trial (BASKET). Lancet 2005;366:921-9.